HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...
If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...
One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end there — up to 30 percent of early-stage breast cancer cases will later ...
Hosted on MSN
Planning ahead with HR+/HER2- MBC: Questions to ask your doctor about treatment progression and what comes next
When you get an HR+/HER2- metastatic breast cancer (MBC) diagnosis, it can feel like your future is out of your hands. Treatment for this type of cancer targets certain receptors on cancer cells, and ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...
Advanced gastroesophageal adenocarcinoma (GEA) with HER2 positivity has long presented significant treatment challenges, with ...
It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!
Adding Ibrance to maintenance therapy extends progression-free survival by 15.2 months in HR-positive, HER2-positive ...
Activation of immune blood biomarkers from interferon gamma pathway distinguished long-term survivors (>=2 years) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results